Gilead Sciences, Inc. (GILD)
167.47 USD -1.68%
Gilead Sciences, Inc. fell 1.68% in the latest session, at 167.47 USD. By market cap it is number 3 of the 5 health care stocks on the Nasdaq-100 heatmap. The price is 4.7% below its 52-week high.
Key numbers
- Price
- 167.47 USD
- Day change
- -1.68% (-2.86)
- Market cap
- 208B USD
- P/E (trailing)
- —
- P/E (forward)
- 16.6
- Dividend yield
- 1.93%
- 50-day average
- 151.36
- 200-day average
- 140.13
- 52-week range
- 116.88 – 175.65
- Dividend per share (annual)
- 3.28 USD
Data as of 3 Nov 2026, 22:00 CET. Market data may be delayed.
Gilead Sciences, Inc. over the past year
From daily closing prices. The highest close in the period was 170.68 USD on 30 Oct 2026, the lowest 118.15 USD on 10 Nov 2025.
| 1 month | 3 months | 6 months | Year to date | 1 year |
|---|---|---|---|---|
| +17.70% | +25.96% | +27.63% | +38.79% | +38.50% |
| Month | Close (USD) | Change |
|---|---|---|
| November 2026 | 170.35 | -0.19% |
| October 2026 | 170.68 | +14.51% |
| September 2026 | 149.05 | +1.85% |
| August 2026 | 146.34 | +12.39% |
| July 2026 | 130.21 | +3.06% |
| June 2026 | 126.34 | -6.02% |
| May 2026 | 134.43 | +2.74% |
| April 2026 | 130.84 | -6.12% |
| March 2026 | 139.37 | -6.43% |
| February 2026 | 148.95 | +4.93% |
| January 2026 | 141.95 | +15.65% |
| December 2025 | 122.74 | -2.46% |
Health care peers
Gilead Sciences, Inc. is on the Nasdaq-100 heatmap (Health care). How it compares with the other health care stocks there, by market cap:
| Company | Today | Market cap | P/E |
|---|---|---|---|
| AstraZeneca PLC AZN | -1.45% | 285B USD | 26.0 |
| Amgen Inc. AMGN | -0.90% | 249B USD | 28.6 |
| Gilead Sciences, Inc. GILD | -1.68% | 208B USD | — |
| Intuitive Surgical, Inc. ISRG | +0.89% | 156B USD | 53.3 |
| Vertex Pharmaceuticals Incorporated VRTX | -4.05% | 134B USD | 34.2 |
More on GILD
Open GILD in zysk for the live chart, news, earnings and dividends, and ask the AI why it moved: it answers in a few lines with sources and a chart (how zysk's AI stock research works). zysk explains facts, news and risks; it is not investment advice.